NICE (UK) terminated evaluation for Breyanzi for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment – BMS

NICE (UK) is unable to make a recommendation about the use in the NHS of lisocabtagene maraleucel for treating relapsed or refractory follicular lymphoma in adults after 2 or more lines of systemic treatment.
This is because Bristol Myers Squibb has confirmed that it does not intend to make an evidence submission for the evaluation. Bristol Myers Squibb considers that there is unlikely to be enough evidence that the technology is a cost-effective use of NHS resources for this population. NICE will review the position if the company decides that it wants to make an evidence submission.